ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,235Medicare Part D Prescriptions Filled, Including Refills

Rank: 65 out of 434

$319K Total Retail Price of All Prescriptions

Rank: 105 out of 434

300 Patients Receiving at Least One Drug in Part D
86%Patients 65 Years and Older
64% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nevada
Lower avg

Schedule Two
Controlled Substances

21% of this provider’s 300 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

21% of this provider’s 300 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

0% of this provider’s 7,085 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$39 was the average price of a prescription from this provider, compared to $52 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 13.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nevada
WARFARIN SODIUM 512 475 1 18
LEVOTHYROXINE SODIUM 279 259 2 3
GABAPENTIN 254 178 3 14
METOPROLOL TARTRATE 239 235 4 12
SIMVASTATIN 232 179 5 2
AMLODIPINE BESYLATE 226 190 6 6
LISINOPRIL 224 207 7 1
FUROSEMIDE 223 210 8 9
HYDROCODONE-ACETAMINOPHEN 220 200 S3 9 4
SERTRALINE HCL 171 171 10 27
OXYCODONE-ACETAMINOPHEN 167 140 S2 11 74
CARVEDILOL 148 143 12 24
MORPHINE SULFATE ER 133 108 S2 13 50
POTASSIUM CHLORIDE 128 125 14 20
HYDROCHLOROTHIAZIDE 126 111 15 8
PREDNISONE 121 109 16 42
ENALAPRIL MALEATE 118 114 17 59
LANTUS SOLOSTAR 111 84 18 71
METFORMIN HCL 98 94 19 7
TAMSULOSIN HCL 96 82 20 29
METFORMIN HCL ER 96 87 20 48
BACLOFEN 91 28 22 77
DIVALPROEX SODIUM 89 80 23 111
ALENDRONATE SODIUM 87 74 24 15
KLOR-CON M20 86 79 25 142
FAMOTIDINE 86 82 25 76
OMEPRAZOLE 85 82 27 5
OXYCODONE HCL 81 61 S2 28 34
SPIRONOLACTONE 79 78 29 70
CARBIDOPA-LEVODOPA 75 50 30 154
HALOPERIDOL 75 60 30 247
NOVOLOG FLEXPEN 75 75 30 138
ZOLPIDEM TARTRATE 70 64 33 11
PRAVASTATIN SODIUM 69 64 34 17
LANTUS 67 67 35 80
ATORVASTATIN CALCIUM 66 64 36 19
METHADONE HCL 57 21 S2 37 108
DONEPEZIL HCL 57 50 37 35
AZITHROMYCIN 56 48 39 38
NITROFURANTOIN MONO-MACRO 54 35 40 279
HYDRALAZINE HCL 51 50 41 79
CIPROFLOXACIN HCL 50 37 42 55
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 21, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.